AI-generated · cited to primary sources · not investment advice
Eli Lilly and Company Common Stock (LLY) Sep 2025 Filing Analysis
Does management do what it says?
The company recognized a $200.0 million sales-based milestone for Jardiance during the current period and confirmed eligibility for up to $410.0 million more in 2026. (1 in progress, 3 revised across 4 tracked commitments)
“As of September 30, 2025, we have the right to receive up to $410.0 million in potential sales-based milestones related to the Jardiance product family in certain markets in 2026.”
The estimated unfunded commitment has been slightly adjusted to $878 million (from $868 million previously) to be paid over the next 10 years. (1 revised across 1 tracked commitment)
“As of September 30, 2025, we had approximately $878 million of unfunded commitments to invest in venture capital funds, which we anticipate will be paid over a period of up to 10 years.”
Management has raised the full-year effective tax rate guidance to 19.8% for the first nine months of 2025, up from the previously guided 19%, primarily due to the unfavorable tax impacts of non-deductible acquired IPR&D charges and the enactment of the OBBBA. (1 revised across 1 tracked commitment)
“The effective tax rates were 22.8 percent and 19.8 percent for the three and nine months ended September 30, 2025, respectively... As a result of the OBBBA, the effective tax rates for the three and nine months ended September 30, 2025 were unfavorably impacted by incremental tax expense recognized in these periods.”
See the full cited Management analysis of Eli Lilly and Company Common Stock
What could break the thesis?
Balance sheet risk is intensifying as total debt increased by $8.86 billion since year-end 2024 to $42.51 billion, primarily to fund acquisitions like Morphic and Scorpion. (1 intensifying, 1 easing, 1 stable)
“As of September 30, 2025, total debt was $42.51 billion, an increase of $8.86 billion compared with $33.64 billion as of December 31, 2024.”
See the full cited Risk analysis of Eli Lilly and Company Common Stock
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.